PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25330767-0 2015 Verapamil modulates interleukin-5 and interleukin-6 secretion in organotypic human sinonasal polyp explants. Verapamil 0-9 interleukin 6 Homo sapiens 38-51 25330767-8 2015 The percent of SEB-stimulated IL-6 secretion (217.53% +- 89.51%) was also significantly reduced following exposure to verapamil (148.82% +- 79.15%, p < 0.05) but not dexamethasone (148.86% +- 145.24%). Verapamil 118-127 interleukin 6 Homo sapiens 30-34 19350266-6 2009 Meanwhile, the levels of IL6 on days 1 and 3 were markedly lower in the Verapamil group than that in control group (P < 0.05 and P < 0.01, respectively. Verapamil 72-81 interleukin 6 Homo sapiens 25-28 14615256-0 2003 Verapamil inhibits interleukin-6 and vascular endothelial growth factor production in primary cultures of keloid fibroblasts. Verapamil 0-9 interleukin 6 Homo sapiens 19-32 17953377-0 2007 [Verapamil effect and influence on postoperative epidural analgesia and cell factors TNFalpha, IL-6 and IL-2]. Verapamil 1-10 interleukin 6 Homo sapiens 95-99 8576944-2 1995 Two Ca(2+)-channel blockers, Manidipine (Roth et al., 1992) and Verapamil (Walz et al., 1990) have been shown to induce the expression of the gene coding for interleukin-6 (IL-6). Verapamil 64-73 interleukin 6 Homo sapiens 158-171 14615256-2 2003 The aim of this study was to evaluate the effect of the calcium antagonist verapamil on the interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) secretion, as well as on cellular growth, in primary cultures of fibroblasts derived from the central part of keloid lesions. Verapamil 75-84 interleukin 6 Homo sapiens 92-105 14615256-2 2003 The aim of this study was to evaluate the effect of the calcium antagonist verapamil on the interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) secretion, as well as on cellular growth, in primary cultures of fibroblasts derived from the central part of keloid lesions. Verapamil 75-84 interleukin 6 Homo sapiens 107-111 14615256-5 2003 Verapamil (100 microM) decreased IL-6 and VEGF production (P<0.03 and P<0.005, respectively) in central keloid fibroblasts cultures at 72 h. Moreover, verapamil decreased cellular proliferation by 29% and increased apoptosis to an absolute value of 8%. Verapamil 0-9 interleukin 6 Homo sapiens 33-37 14615256-6 2003 The results of this study demonstrate that in primary cultures of central keloid fibroblasts verapamil reduces the sustained basal IL-6 and VEGF production and inhibits cell growth; these data may offer the link with the beneficial effect of calcium antagonists on keloid scars in vivo. Verapamil 93-102 interleukin 6 Homo sapiens 131-135 10226093-2 1999 We investigated the underlying molecular mechanism responsible for IL-6 induction in response to the CCB amlodipine, diltiazem, and verapamil in primary human vascular smooth muscle cells (VSMC). Verapamil 132-141 interleukin 6 Homo sapiens 67-71 8576944-2 1995 Two Ca(2+)-channel blockers, Manidipine (Roth et al., 1992) and Verapamil (Walz et al., 1990) have been shown to induce the expression of the gene coding for interleukin-6 (IL-6). Verapamil 64-73 interleukin 6 Homo sapiens 173-177 3966907-4 1985 In HSF and SMC, a delay in 125I-LDL degradation and hydrolysis of 3H-CL was seen in cells treated for 3 to 24 hours with verapamil. Verapamil 121-130 interleukin 6 Homo sapiens 3-6 1496542-1 1992 We studied the effect of cyclosporine A, prednisolone, and the Ca2+ channel blocker verapamil on interleukin-6 binding to mitogen-activated peripheral blood mononuclear cells, using a flow cytometric technique and phycoerythrin-conjugated IL-6. Verapamil 84-93 interleukin 6 Homo sapiens 97-110 3006091-2 1986 The specific binding and internalization of human 125I-labeled LDL are dose-dependently increased in HSF by CA of the verapamil series (verapamil, anipamil, gallopamil, ronipamil, and diltiazem), but neither by CA of the dihydropyridine series (nifedipine, nitrendipine) nor by flunarizine. Verapamil 118-127 interleukin 6 Homo sapiens 101-104 3006091-2 1986 The specific binding and internalization of human 125I-labeled LDL are dose-dependently increased in HSF by CA of the verapamil series (verapamil, anipamil, gallopamil, ronipamil, and diltiazem), but neither by CA of the dihydropyridine series (nifedipine, nitrendipine) nor by flunarizine. Verapamil 136-145 interleukin 6 Homo sapiens 101-104 7497600-2 1995 R-verapamil caused a dose-dependent inhibition of AML blast proliferation in the presence of stem-cell factor, leukemia inhibitory factor, interleukin 4, interleukin 6, and interleukin 10 when these cytokines were tested both alone and in different combinations. Verapamil 0-11 interleukin 6 Homo sapiens 154-167 2341719-0 1990 Transcriptional modulation of human IL-6 gene expression by verapamil. Verapamil 60-69 interleukin 6 Homo sapiens 36-40 2341719-3 1990 In sharp contrast, the addition of verapamil to PHA and PMA-stimulated PBMC augmented the mitogen-stimulated increases in nuclear transcription of IL-6-encoding mRNA, steady state levels of IL-6 encoding mRNA, and release of IL-6 bioactivity. Verapamil 35-44 interleukin 6 Homo sapiens 147-151 2341719-3 1990 In sharp contrast, the addition of verapamil to PHA and PMA-stimulated PBMC augmented the mitogen-stimulated increases in nuclear transcription of IL-6-encoding mRNA, steady state levels of IL-6 encoding mRNA, and release of IL-6 bioactivity. Verapamil 35-44 interleukin 6 Homo sapiens 190-194 2341719-3 1990 In sharp contrast, the addition of verapamil to PHA and PMA-stimulated PBMC augmented the mitogen-stimulated increases in nuclear transcription of IL-6-encoding mRNA, steady state levels of IL-6 encoding mRNA, and release of IL-6 bioactivity. Verapamil 35-44 interleukin 6 Homo sapiens 190-194 2341719-6 1990 We suggest that a non-calcium-dependent, IL-6 regulatory factor, absent or inactive in verapamil-treated cultures, inhibits IL-6 gene activation in mitogen-stimulated PBMC. Verapamil 87-96 interleukin 6 Homo sapiens 41-45 2341719-6 1990 We suggest that a non-calcium-dependent, IL-6 regulatory factor, absent or inactive in verapamil-treated cultures, inhibits IL-6 gene activation in mitogen-stimulated PBMC. Verapamil 87-96 interleukin 6 Homo sapiens 124-128 3966907-5 1985 Pretreatment of HSF with 50 microM verapamil for 24 hours and incubation with 2 to 50 micrograms 125I-LDL protein/ml for 1 hour resulted in a 50% to 200% increase in heparin releasable and in a 40% to 130% increase in cellular 125I-LDL. Verapamil 35-44 interleukin 6 Homo sapiens 16-19